NASDAQ$TNDM
Tandem Diabetes Care Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Tandem Diabetes Care's Q2 2020 financial results were announced with sales guidance for the year ending December 31, 2020.
Tandem Diabetes Care reported a 17% increase in worldwide sales, reaching $109.2 million for the second quarter of 2020. The company successfully completed its first acquisition and executed multiple agreements. They are reinstating the sales guidance they set at the beginning of 2020.
- Worldwide sales increased 17% to $109.2 million compared to Q2 2019.
- Domestic pump shipments increased 15% to 14,735 pumps.
- International pump shipments decreased 53% to 3,952 pumps.
- Company is reinstating its sales guidance estimated to be in the range of $450 million to $465 million for the year ending December 31, 2020.
Headline financials
Revenue & EPS history
Tandem Diabetes · Revenue · Quarterly
$109M
Revenue by segment
Tandem Diabetes · $80.7M total across 1 segment · Q3 2022
- Pump Sales$80.7M—100.0%
Forward guidance
The Company is reinstating its sales guidance estimated to be in the range of $450 million to $465 million, which includes international sales of approximately $70 million to $75 million for the year ending December 31, 2020.
Tailwinds
- Continued strong worldwide demand for our t:slim X2 insulin pump.
- Positive feedback from users of our Control-IQ technology
- Scaling international launch
- UnitedHealthcare’s recent decision to include Tandem as a network provider.
- Annual sales growth of 24 percent to 28 percent compared to 2019.
Headwinds
- Being mindful of the unpredictable nature of the current pandemic.
- Market acceptance of the Company’s existing products and products under development by physicians and people with diabetes
- Company’s ability to establish and sustain operations to support international sales, including expansion into additional geographies
- Changes in reimbursement rates or insurance coverage for the Company’s products
- The depth and duration of the evolving COVID-19 pandemic, and the global response thereto
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.4%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+3.5%
Avg return
30 days after
55%
27 / 49 earnings
Positive
+32.8%
Q4 2025
Best reaction
-63.6%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.6% | -23.6% | +5.0% | |
| Q4 2025 | +32.8% | +40.4% | +34.0% | |
| Q3 2025 | +22.0% | +35.5% | +56.9% | |
| Q1 2025 | +18.6% | +26.5% | +17.6% | |
| Q4 2024 | -35.2% | -42.0% | -42.6% | |
| Q3 2024 | +0.6% | -5.3% | -9.1% | |
| Q2 2024 | +12.7% | +17.3% | +17.6% | |
| Q1 2024 | +23.5% | +21.5% | +41.5% | |
| Q4 2023 | +6.1% | +22.5% | +28.4% | |
| Q3 2023 | -12.1% | -11.5% | +22.5% | |
| Q2 2023 | +2.8% | -13.4% | -14.3% | |
| Q1 2023 | -2.9% | -13.4% | -35.9% | |
| Q4 2022 | -2.1% | -8.0% | +8.0% | |
| Q3 2022 | -34.3% | -31.5% | -23.7% | |
| Q2 2022 | -14.0% | -11.8% | -34.3% | |
| Q1 2022 | -16.4% | -27.6% | -33.8% | |
| Q4 2021 | -0.3% | +7.6% | +7.6% | |
| Q3 2021 | -4.9% | -2.6% | -4.3% | |
| Q2 2021 | +4.7% | +2.6% | +8.8% | |
| Q1 2021 | -5.6% | -11.9% | -5.8% | |
| Q4 2020 | +3.5% | +4.4% | -10.0% | |
| Q3 2020 | +1.5% | -11.4% | -17.9% | |
| Q2 2020 | +1.8% | +3.0% | +10.1% | |
| Q1 2020 | +7.6% | +13.7% | +11.5% | |
| Q4 2019 | -11.4% | -15.2% | -34.7% | |
| Q3 2019 | -6.5% | -8.0% | +2.2% | |
| Q2 2019 | +2.9% | -1.5% | +14.2% | |
| Q1 2019 | -5.8% | +6.3% | +9.2% | |
| Q4 2018 | +27.9% | +43.2% | +31.8% | |
| Q3 2018 | +6.3% | -2.2% | -2.1% | |
| Q2 2018 | +7.7% | +29.0% | +59.9% | |
| Q1 2018 | +7.9% | +7.7% | +96.4% | |
| Q4 2017 | +23.1% | +25.0% | +57.0% | |
| Q3 2017 | -3.4% | -6.4% | +2.7% | |
| Q2 2017 | -17.3% | -39.4% | +8.7% | |
| Q1 2017 | -11.8% | -10.5% | -22.4% | |
| Q4 2016 | -19.1% | -10.6% | -51.1% | |
| Q3 2016 | -63.6% | -66.9% | -63.2% | |
| Q2 2016 | -13.9% | -18.8% | -8.4% | |
| Q1 2016 | +7.1% | — | — | |
| Q4 2015 | +11.9% | — | — | |
| Q3 2015 | +20.6% | — | — | |
| Q2 2015 | +8.9% | — | — | |
| Q1 2015 | +1.7% | — | — | |
| Q4 2014 | -3.1% | — | — | |
| Q3 2014 | -11.0% | — | — | |
| Q2 2014 | +11.4% | — | — | |
| Q1 2014 | -11.7% | — | — | |
| Q4 2013 | +4.0% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro